How have SRZN shares performed in 2024?

Surrozen's stock was trading at $9.40 on January 1st, 2024. Since then, SRZN stock has decreased by 0.7% and is now trading at $9.33. View the best growth stocks for 2024 here .

Are investors shorting Surrozen?

Surrozen saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 7,900 shares, an increase of 132.4% from the March 15th total of 3,400 shares. Based on an average daily trading volume, of 17,800 shares, the days-to-cover ratio is presently 0.4 days. Approximately 0.6% of the shares of the stock are short sold. View Surrozen's Short Interest .

When is Surrozen's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024. View our SRZN earnings forecast .

How were Surrozen's earnings last quarter?

Surrozen, Inc. (NASDAQ:SRZN) issued its earnings results on Monday, November, 15th. The company reported ($7.65) EPS for the quarter, missing analysts' consensus estimates of ($5.85) by $1.80.

When did Surrozen's stock split?

Shares of Surrozen reverse split before market open on Thursday, December 14th 2023. The 1-15 reverse split was announced on Thursday, December 14th 2023. The number of shares owned by shareholders was adjusted after the market closes on Thursday, December 14th 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

How do I buy shares of Surrozen?

Shares of SRZN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:SRZN

Surrozen (SRZN) Stock Price, News & Analysis

→ Biden’s $374B Giveaway Into This Sector (From DTI) (Ad)

Free SRZN Stock Alerts

$9.33

-0.03 (-0.32%)

(As of 04/18/2024 ET)

Compare

Today's Range: $9.33
▼
$10.75
50-Day Range: $8.75
▼
$15.71
52-Week Range: $4.50
▼
$16.19

Volume: 28,590 shs
Average Volume: 27,592 shs
Market Capitalization: $19.03 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Get Surrozen alerts:

Surrozen MarketRank™ Stock Analysis

Analyst Rating: N/A
Upside/Downside: N/A
Short Interest: Healthy
0.56% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.54
Based on 3 Articles This Week
Insider Trading: Acquiring Shares
$3 M Bought Last Quarter
Proj. Earnings Growth: Growing
From ($9.19) to ($2.85) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.19 out of 5 stars

Medical Sector

530th out of 918 stocks

Biological Products, Except Diagnostic Industry

80th out of 147 stocks

N/A

Analyst's Opinion

Consensus Rating
There is not enough analysis data for Surrozen.

3.0

Short Interest

Percentage of Shares Shorted
0.56% of the float of Surrozen has been sold short.
Short Interest Ratio / Days to Cover
Surrozen has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Surrozen has recently increased by 132.35%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Surrozen does not currently pay a dividend.
Dividend Growth
Surrozen does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for SRZN.

2.5

News and Social Media Coverage

News Sentiment
Surrozen has a news sentiment score of 0.54. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 3 news articles for Surrozen this week, compared to 0 articles on an average week.
Search Interest
Only 1 people have searched for SRZN on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
MarketBeat Follows
4 people have added Surrozen to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

5.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Surrozen insiders have bought more of their company's stock than they have sold. Specifically, they have bought $2,999,994.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
35.00% of the stock of Surrozen is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
66.57% of the stock of Surrozen is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Surrozen are expected to grow in the coming year, from ($9.19) to ($2.85) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Surrozen is -0.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Surrozen is -0.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Surrozen has a P/B Ratio of 0.50. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad DTI

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

Click here for the full story

About Surrozen Stock (NASDAQ:SRZN)

Surrozen, Inc., a clinical stage biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair and regeneration. The company is developing antibody-based therapeutics with application across various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. Its products in pipeline include SZN-043, a hepatocyte-specific R-spondin mimetic bispecific fusion protein, which is in Phase 1b clinical trial for the treatment of severe liver diseases, including alcoholic hepatitis and asialoglycoprotein receptor 1; and SZN-1326, a bi-specific antibody, which is in Phase 1b clinical trial for the treatment of moderate to severe inflammatory bowel disease, Frizzled, and LRP receptors. The company also develops SZN-413, a Fzd4 targeted bi-specific antibody, which is in preclinical stage for the treatment of retinal vascular associated diseases. Surrozen, Inc. has collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies. Surrozen, Inc. was founded in 2015 and is based in South San Francisco, California.

SRZN Stock Price History

30 days | 90 days | 365 days | Advanced Chart

SRZN Stock News Headlines

April 9, 2024 | insidertrades.com

Insider Buying: Surrozen, Inc. (NASDAQ:SRZN) Director Buys 193,548 Shares of Stock

April 18, 2024 | msn.com

Surrozen files to sell 1.09M shares of common stock for holders

April 19, 2024 | InvestorPlace (Ad)

New crypto project uncovers 2,050% in 65 days

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

April 18, 2024 | msn.com

Surrozen (SRZN) Price Target Decreased by 40.00% to 20.66

April 10, 2024 | uk.investing.com

Surrozen director Tim Kutzkey acquires $3m in company stock

April 3, 2024 | globenewswire.com

Surrozen Publishes Study in 'Respiratory Research' Demonstrating the Promise of a Wnt Mimetic Antibody in Treating Pulmonary Fibrosis

April 1, 2024 | msn.com

U.S. shares mixed at close of trade; Dow Jones Industrial Average down 0.60%

April 1, 2024 | msn.com

Why Is Regenerative Medicine-Focused Surrozen Stock Trading Lower On Monday?

April 19, 2024 | InvestorPlace (Ad)

New crypto project uncovers 2,050% in 65 days

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

April 1, 2024 | globenewswire.com

Surrozen Announces Safety, Pharmacodynamic and Liver Function Data for SZN-043

April 1, 2024 | globenewswire.com

Surrozen Announces up to $192.5 Million Private Placement of Securities Priced At-the-Market Under Nasdaq Rules

February 8, 2024 | msn.com

Surrozen Promotes Charles Williams to COO with CFO Role

January 18, 2024 | finanznachrichten.de

Surrozen, Inc.: Surrozen Provides Corporate Update on Clinical Programs

January 18, 2024 | ca.finance.yahoo.com

Surrozen, Inc. (SRZNW) Stock Price, News, Quote & History - Yahoo Finance

January 18, 2024 | finance.yahoo.com

Surrozen Provides Corporate Update on Clinical Programs

January 3, 2024 | finance.yahoo.com

We're Keeping An Eye On Surrozen's (NASDAQ:SRZN) Cash Burn Rate

November 10, 2023 | stocknews.com

3 Biotech Stocks to Watch in November

November 9, 2023 | msn.com

Surrozen GAAP EPS of -$0.34 misses by $0.03

November 8, 2023 | finance.yahoo.com

Surrozen Provides Third Quarter 2023 Financial Results

November 4, 2023 | morningstar.com

Surrozen Inc Ordinary Shares SRZN

August 20, 2023 | finanznachrichten.de

Surrozen, Inc.: Surrozen Provides Second Quarter 2023 Financial Results

August 10, 2023 | msn.com

Surrozen GAAP EPS of -$0.31

August 9, 2023 | finance.yahoo.com

Surrozen Provides Second Quarter 2023 Financial Results

July 21, 2023 | finance.yahoo.com

Is Surrozen (NASDAQ:SRZN) In A Good Position To Deliver On Growth Plans?

June 5, 2023 | finance.yahoo.com

Surrozen Publishes Study in Nature Communications Demonstrating the Promise of a Fzd4 Wnt Antibody in Treating Ischemic Stroke

May 15, 2023 | finanznachrichten.de

Surrozen, Inc.: Surrozen Provides First Quarter 2023 Financial Results and Corporate and Pipeline Updates

May 13, 2023 | msn.com

Surrozen GAAP EPS of -$0.48 misses by $0.07

See More Headlines

Receive SRZN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Surrozen and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/15/2021
Today: 4/19/2024
Next Earnings (Estimated): 5/08/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Current Symbol: NASDAQ:SRZN
CUSIP: N/A
CIK: 1824893
Web: www.consonancehfw.com
Phone: 650-489-9000
Fax: N/A
Employees: 74
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($17.3914)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-43,040,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -82.43%
Return on Assets: -69.74%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 5.75
Quick Ratio: 5.75

Sales & Book Value

Annual Sales: $12.50 million
Price / Sales: 1.52
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $18.60 per share
Price / Book: 0.50

Miscellaneous

Outstanding Shares: 2,040,000
Free Float: 1,325,000
Market Cap: $19.03 million
Optionable: Not Optionable
Beta: 0.74

10 "Recession Proof" Stocks That Will Thrive in Any Market

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

Mr. Craig C. Parker M.B.A. (Age 62)
CEO, President & Director
Comp: $753.3k
Mr. Charles Williams (Age 43)
CFO, COO & Corporate Secretary
Comp: $563.49k
Dr. K. Christopher Garcia Ph.D.
Co-Founder & Member of Scientific Advisor
Dr. Roeland Nusse Ph.D. (Age 74)
Co-Founder & Member of Scientific Advisor
Dr. Calvin Kuo M.D.
Ph.D., Co-Founder & Member of Scientific Advisor
Dr. Li Yang Ph.D.
Executive Vice President of Research
Esther Jhun
Controller

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

SRZN Stock Analysis - Frequently Asked Questions

How have SRZN shares performed in 2024?: Surrozen's stock was trading at $9.40 on January 1st, 2024. Since then, SRZN stock has decreased by 0.7% and is now trading at $9.33.
View the best growth stocks for 2024 here.
Are investors shorting Surrozen?: Surrozen saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 7,900 shares, an increase of 132.4% from the March 15th total of 3,400 shares. Based on an average daily trading volume, of 17,800 shares, the days-to-cover ratio is presently 0.4 days. Approximately 0.6% of the shares of the stock are short sold.
View Surrozen's Short Interest.
When is Surrozen's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024.
View our SRZN earnings forecast.
How were Surrozen's earnings last quarter?: Surrozen, Inc. (NASDAQ:SRZN) issued its earnings results on Monday, November, 15th. The company reported ($7.65) EPS for the quarter, missing analysts' consensus estimates of ($5.85) by $1.80.

When did Surrozen's stock split?: Shares of Surrozen reverse split before market open on Thursday, December 14th 2023. The 1-15 reverse split was announced on Thursday, December 14th 2023. The number of shares owned by shareholders was adjusted after the market closes on Thursday, December 14th 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.
How do I buy shares of Surrozen?: Shares of SRZN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:SRZN) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial